Clinical Trial Update: Tagraxofusp-erzs, an IL-3 Diphtheria Fusion Protein, in Combination With Gemtuzumab Ozogamicin in Patients With Relapsed/Refractory AML [Phase 1]

View source ↗

Summary

Phase 1 trial update evaluating Tagraxofusp-erzs in combination with gemtuzumab ozogamicin for relapsed/refractory acute myeloid leukemia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Gemtuzumab ozogamicin (gemtuzumab ozogamicin)
• Tagraxofusp-erzs (tagraxofusp)

Snippet

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Conditions: Acute Myeloid Leukemia | Phase 1 | Status: ACTIVE_NOT_RECRUITING